У нас вы можете посмотреть бесплатно Episode 12 | 2025 Year in Review & Plans for 2026 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Proof of DeSci 2025 Year in Review & Plans for 2026 2025 marked a turning point for ValleyDAO, a year defined by growth, maturation, and real-world validation of decentralized science. Read the End of 2025 Report: / 2025-year-in-review-when-desci-stopped-bei... In this episode, we look back at the milestones that shaped the ecosystem, from expanding the core team and advancing flagship research projects to strengthening governance and pushing technologies closer to commercialization. Albert and Morgan join us to unpack what it actually takes to fund climate biotech, translate research into viable products, and build infrastructure that supports scientists beyond traditional funding models. We dive into: • Hempy’s transition from funded research to a market-ready biotech hoodie • Cocoa Zero’s progress toward locally produced, sustainable fats • Tattva’s carbon-negative construction materials • Primordia and the rise of community-driven biotech experimentation • The role of the $GROW token in supporting innovation • Phlo, ValleyDAO’s AI-powered platform designed to help researchers de-risk technologies, develop business models, and secure funding We also discuss the realities of building in DeSci, navigating crypto cycles, staying science-first, and attracting contributors capable of turning ambition into execution. Looking ahead, 2026 is about pilots, partnerships, and deployment: integrating ValleyDAO technologies with industry, publicly launching Phlo, and continuing to bridge the gap between research and real-world impact. If you’re curious about where decentralized science is heading, and how biotech moves from lab benches to scalable solutions, this conversation is for you.